ArticleJournal for immunotherapy of cancer2024

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.

David G Coffey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.